EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of altered potassium channels for drug repurposing in long COVID patients

John P. George, Kiran Bharat Gaikwad, Jyoti Sharma

Frontiers in Bioinformatics · 09.11.2026 · 6

DOI: 10.3389/fbinf.2026.1915857 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioinformatics, online erschienen am 09.11.2026. Verfasst von John P. George und 2 weiteren Autor:innen. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Long COVID (LC) is a complex condition characterized by persistent, chronic multisystem manifestations, with a significant proportion of patients exhibiting neurological symptoms. Human ion channels (HICs), particularly potassium channels, are abundantly expressed in the nervous system and are involved in key physiological processes, making them potential candidates for understanding LC pathophysiology and identifying opportunities for drug repurposing. Methodology Meta-analysis of RNA sequencing datasets from COVID-19-recovered and LC patients was performed. Differential gene expression analysis, functional enrichment analysis, and weighted gene co-expression network analysis were performed to uncover key genes, pathways, and co-expression modules consisting of HICs, lipid metabolism-, and immune signaling-related genes. Drug-gene interaction analysis was performed using the Drug-Gene Interaction Database and Connectivity Map to identify potential ion channel candidates for drug repurposing.

Results

A total of 715 dysregulated genes, including 18 HICs, were identified, among which seven were potassium channels. Three significant modules containing HICs, lipid metabolism-, and immune signaling-related genes were identified and found to be associated with antigen processing and presentation, complement and coagulation cascades, and cytokine-related pathways. Additionally, drug interaction analysis identified approved drugs targeting KCNA6 , KCNJ10 , KCNN3 , and KCNH4 .

Conclusion

These findings provide insights into a subset of molecular alterations underlying the multisystem dysregulation observed in LC. The identified drug interactions may provide opportunities for drug repurposing to address neurological manifestations of LC. Further experimental validation is required to establish their therapeutic efficacy and potential clinical relevance.

Zitieren

APA

George, J. P., Gaikwad, K. B., & Sharma, J. (2026). Identification of altered potassium channels for drug repurposing in long COVID patients. Frontiers in Bioinformatics, 6. https://doi.org/10.3389/fbinf.2026.1915857

Vancouver

George JP, Gaikwad KB, Sharma J. Identification of altered potassium channels for drug repurposing in long COVID patients. Frontiers in Bioinformatics. 2026;6. doi:10.3389/fbinf.2026.1915857

BibTeX
@article{George2026,
  author = {George, John P. and Gaikwad, Kiran Bharat and Sharma, Jyoti},
  title = {Identification of altered potassium channels for drug repurposing in long COVID patients},
  journal = {Frontiers in Bioinformatics},
  year = {2026},
  volume = {6},
  doi = {10.3389/fbinf.2026.1915857}
}
Kostenlos starten →